Becton Dickinson & Co. closed 20.98% short of its 52-week high of $251.99, which the company reached on February 3rd.

This was the stock's third consecutive day of losses.

Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major ...

Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm ...

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Dexcom (DXCM – Research Report), with a price target of ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Edwards Lifescienes also reported a big increase in pay for the structural heart device developer and manufacturer's median ...

Pharma and biotech companies are breathing a sigh of relief after the tariffs announced by President Donald Trump Wednesday afternoon excludes pharmaceuticals.

In the first trial in hundreds of Georgia lawsuits, retired truck driver Gary Walker, 75, contends emmissions from ethylene oxide caused his cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The global pharmaceutical unit dose packaging market is expected to attain an impressive valuation of USD 34.2 billion in ...

The Africa IVD market is being propelled by several key drivers and emerging trends that are reshaping the diagnostic ...